UTHR Description — United Therapeutics Corp

United Therapeutics is a biotechnology company. Co. markets and sells four commercial therapies to treat pulmonary arterial hypertension (PAH): Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection for treatment of high-risk neuroblastoma. Co. also engages in research and development of new indications and formulations and delivery devices for its existing products, as well as new products to treat PAH and other conditions. Co. also engages in organ transplantation-related technologies.

Company Name: 
United Therapeutics Corp
Number of ETFs Holding UTHR: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   UTHR Weight   UTHR Amount 
 VTI   0.02%   $145,981,269         
 IJH   0.33%   $143,402,670         
 VB   0.14%   $128,248,916         
 XBI   2.04%   $107,502,728         
 VBR   0.29%   $78,571,590         
 VXF   0.11%   $74,413,098         
 FBT   3.52%   $72,906,239         
 IBB   0.56%   $49,172,384         
 MDY   0.33%   $48,135,734         
 IJJ   0.75%   $33,239,388         
List of all 54 ETFs holding UTHR »
Quotes delayed 20 minutes

Buy (3.29 out of 4)
53rd percentile
(ranked higher than approx. 53% of all stocks covered)

Analysts Forecast:
UTHR Price Target

Based on data provided by Zacks Investment Research via

ETFs Holding UTHR | United Therapeutics Corp | ETF Channel |

Copyright © 2010 - 2020, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.